Development of a Blood Test for Colorectal Cancer based on Metabolomic Signature

基于代谢组学特征的结直肠癌血液检测的开发

• 批准号: 523397-2018
• 负责人: Bathe, Oliver
• 金额: $ 23.34万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=694818
• 关键词: Development; Blood; Test; Colorectal; Cancer

Colorectal cancer (CRC) is the second leading cause of cancer death in the western world.Ideally, CRC will be detected early because treatments become progressively morecomplicated, toxic and expensive in later disease stages, and the survival is best in earlystage of disease. That is the basis of screening. Currently, the gold standard screening test iscolonoscopy, which is invasive, expensive and difficult to perform on large populations. Onestrategy is to enrich the subgroup that requires a colonoscopy by doing a stool test (called afecal immunohistochemical test, FIT). The problem is that compliance for stool tests is lessthan 40% because testing stool is objectionable and inconvenient. We have developed ablood test based on the chemical composition of serum. This test is quite sensitive and it hasalready been tested on over 600 patients. In this project, in collaboration with Med-LifeDiscoveries and Innovate Calgary, as well as a multidisciplinary science team, we will furtherrefine the test, then create a diagnostic test that can be used in a typical clinical laboratory.Software will be developed to enhance the capability to analyze test results. Finally, we willtest the new diagnostic test on blood samples collected from close to 3500 individuals whohad screening colonoscopies. At the end, we will have a convenient, clinically applicable testthat will be tested in the future in a larger clinical trial that would inform regulatory agenciesand clinicians on the value of this new test as an alternative screening tool.

结直肠癌（Colorectal cancer，CRC）是西方国家癌症死亡的第二大原因，理想情况下，CRC应尽早发现，因为在疾病晚期，治疗会变得越来越复杂、毒性和昂贵，而在疾病早期，生存率最高。这是筛选的基础。目前，筛查测试的金标准是结肠镜检查，该检查具有侵入性、昂贵且难以在大量人群中进行。一种策略是通过粪便试验（称为粪免疫组化试验，FIT）来丰富需要结肠镜检查的亚组。问题是，粪便测试的依从性低于40%，因为测试粪便令人反感且不方便。我们根据血清的化学成分发展了abbestion试验。这项测试非常敏感，已经在600多名患者身上进行了测试。在这个项目中，与Med-LifeDiscoveries和Innovate Calgary以及一个多学科科学团队合作，我们将进一步完善测试，然后创建一个可用于典型临床实验室的诊断测试。软件将被开发以增强分析测试结果的能力。最后，我们将对从近3500名接受过结肠镜检查的人中采集的血液样本进行新的诊断测试。最后，我们将有一个方便的，临床上适用的测试，将在未来的一个更大的临床试验中进行测试，将告知监管机构和临床医生这种新测试作为替代筛查工具的价值。